by Richard Daverman, PhD
October 15, 2013 -- Miraculins, a Canadian maker of non-invasive diagnostic tests, has signed a Letter of Intent to sell China rights for a diabetes test to Cachet Pharma, a China drug distributor. Miraculins acquired rights to the SCOUT DS® technology less than two months ago. SCOUT is a non-invasive test that measures changes in a person’s skin to indicate prediabetes and diabetes type 2. More details....
Stock Symbols: (TSX-V: MOM) (SHE: 002462)
Help employers find you! Check out all the jobs and post your resume.
